Found: 6
Select item for more details and to access through your institution.
Occurrence of <italic>Pseudomonas aeruginosa</italic> in waters: implications for patients with cystic fibrosis (CF).
- Published in:
- Letters in Applied Microbiology, 2018, v. 66, n. 6, p. 537, doi. 10.1111/lam.12876
- By:
- Publication type:
- Article
Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?—Results of an in vitro study.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2018, v. 43, n. 6, p. 836, doi. 10.1111/jcpt.12722
- By:
- Publication type:
- Article
Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)- CFTR treated with ivacaftor-Changes in microbiological parameters.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2018, v. 43, n. 1, p. 92, doi. 10.1111/jcpt.12616
- By:
- Publication type:
- Article
Determination of optimum incubation time for release of bacteria from sputum of patients with cystic fibrosis using dithiothreitol (Sputasol).
- Published in:
- British Journal of Biomedical Science, 2010, v. 67, n. 2, p. 89, doi. 10.1080/09674845.2010.11978195
- By:
- Publication type:
- Article
Molecular conservation within LES9F and PS21 Liverpool epidemic strain (LES) markers in wild-type clinical Pseudomonas aeruginosa isolated from the sputum of adult patients with cystic fibrosis.
- Published in:
- British Journal of Biomedical Science, 2010, v. 67, n. 2, p. 87, doi. 10.1080/09674845.2010.11978193
- By:
- Publication type:
- Article
Do equine strains of Pseudomonas aeruginosa carry the Liverpool epidemic strain markers relevant to patients with cystic fibrosis?
- Published in:
- British Journal of Biomedical Science, 2010, v. 67, n. 1, p. 30, doi. 10.1080/09674845.2010.11978181
- By:
- Publication type:
- Article